Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
- None.
- None.
The collaboration between Gabather AB and the Centre for Neuropsychiatric Schizophrenia Research represents a significant milestone in the development of GT-002 as a potential treatment for schizophrenia. The investment from the Innovation Fund Denmark underscores the importance of this research, as it enables a phase II clinical study that could have a profound impact on the schizophrenia treatment landscape. This phase of clinical testing is critical because it examines the efficacy of the drug and its side effects in a controlled environment, which is a decisive factor for further development and potential commercialization.
From an investment perspective, the outcomes of this study could substantially affect Gabather's stock valuation. Positive results would likely attract additional funding and partnerships, whereas negative outcomes could diminish investor confidence. The focus on EEG patterns and cognitive parameters is particularly noteworthy, as these are tangible, objective measures that can provide strong evidence of GT-002's therapeutic potential. This aligns with the growing trend in psychiatric drug development to seek biomarkers that can guide treatment decisions and predict responses.
The financial implications of the clinical trial for Gabather AB hinge on the potential market for schizophrenia treatments, which is substantial given the chronic nature of the disease and the need for improved therapeutic options. The budget of 18.6 MSEK (approximately 12 MDKK) for the study is a significant investment that reflects the high costs associated with clinical trials, particularly in neuroscience where long trial durations and complex assessments are common.
Investors should note that while the funding from the Innovation Fund Denmark mitigates some financial risk, the inherent volatility of biotech investing remains. The trial's success could position Gabather as a leader in GABA system-targeted therapies, a niche but growing area in neuropsychiatric drug development. However, it's essential to consider the long development timelines and the possibility of regulatory hurdles post-trial. The stock market reaction will likely be tied to the trial's progress updates and results, with potential for both short-term fluctuations and long-term value changes depending on the perceived success of GT-002.
Understanding the potential impact of GT-002 on schizophrenia treatment requires a grasp of the GABA system's role in neuropsychiatric disorders. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the brain and is involved in regulating neuronal excitability. Dysregulation of the GABA system has been implicated in the pathophysiology of schizophrenia, particularly in relation to cognitive deficits and negative symptoms, which are notoriously difficult to treat.
The emphasis on EEG alpha band power as a biomarker is noteworthy, given its association with cognitive functions and the potential to objectively measure treatment effects. If GT-002 can modulate this biomarker effectively, it may offer a novel approach to managing symptoms that current antipsychotics do not adequately address. This could represent a significant advancement in the field, as treatment options that improve cognitive outcomes and quality of life are in high demand among patients and clinicians alike.
Funded by an Investment Agreement from the Innovation Fund Denmark (IFD), it will now be possible to conduct the first study with GT-002 in patients with schizophrenia. The study is a double-blind randomised so-called phase II study investigating the effect of GT-002 compared to placebo and an active comparator. The 3-year study, aiming at recruiting 20 patients and 30 healthy volunteers will be conducted by the Centre for Neuropsychiatric Schizophrenia Research (CNSR), with Professor Bjørn H. Ebdrup, head of research at the CNSR, as the Principal Investigator. CNSR is a well-recognised psychiatric centre with many years of experience seeing patients with different neuropsychiatric disorders.
"Rarely has the timing of a project been better than in this case; while within schizophrenia research we are uncovering several new connections between schizophrenia and the GABA system, the collaboration with Gabather gives us the opportunity to test the clinical significance of actively influencing the GABA system in patients with schizophrenia. If our studies show positive results, the collaboration will provide optimal conditions to quickly proceed with necessary additional studies, which will ultimately benefit patients" Professor Bjørn H. Ebdrup states.
GT-002 has completed 3 clinical trials in healthy volunteers and has been shown to be safe and well tolerated. The most recent target engagement study showed clinically relevant effects of GT-002 on modulation of EEG frequency band power with a significant increase in alpha band power. This effect spanned various brain regions, including frontal and occipital areas. The results suggest a distinct effects of GT-002 to modulate alpha band power across specific cortical regions. EEG alpha band power is recognised as a marker of cognitive activity such as attention and is associated with relaxation and reduced anxiety. Modulation of EEG alpha band power could be beneficial for several neuropsychiatric conditions, especially negative symptoms in schizophrenia that has been shown to be associated with reduced EEG alpha band power.
"This clinical trial in patients with schizophrenia represents a major step forward in the development of the main asset in our pipeline, GT-002. A positive study outcome could serve as a cornerstone for the development of innovative therapeutic options for the treatment of schizophrenia and improve the quality of life for individuals suffering from diverse neuropsychiatric disorders, a long term goal for the drug development projects at Gabather AB" says Michael-Robin Witt, CEO of Gabather AB.
About GT-002
GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in a discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in an in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZDs), and has not shown any of the side effects known for BZDs. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing. A recently completed EEG/fMRI target engagement study in healthy volunteers shows that GT-002 modulates brain activity across different brain regions and neuronal networks, indicating a unique profile of GT-002 for the treatment of different neuropsychiatric disorders.
Contact Information
Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: mrw@gabather.com
About Gabather
Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders. The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients.
For more information, please visit: www.gabather.com
Certified Adviser
Corpura Fondkommission AB
Phone: +4672-252 34 51
Email: ca@corpura.se
www.corpura.se
Forward-looking statement
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release. Gabather is listed on First North Growth Market and Corpura Fondkommission AB is Certified Advisor.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Public/11735/3959361/83716a10d517e4b0.pdf | PM Schizophrenia trial 2024-04-10 |
View original content:https://www.prnewswire.com/news-releases/gabather-joins-forces-with-the-centre-for-neuropsychiatric-schizophrenia-research-in-denmark-to-conduct-a-clinical-phase-ii-study-with-gt-002-302113046.html
SOURCE Gabather AB
FAQ
What is the purpose of the Collaborative Agreement signed by Gabather AB (GABA)?
Who is funding the clinical trial for GT-002 in patients with schizophrenia?
What are the potential benefits of the study findings for patients with schizophrenia?
What were the results of GT-002 in healthy volunteers from previous clinical trials?
Who is the Principal Investigator for the clinical phase II study with GT-002?
